Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

1. Sweeney, C.
2. Bracarda, S.
3. Sternberg, C.N.
4. Chi, K.N.
5. Olmos, D.
6. Sandhu, S.
7. Massard, C.
8. Matsubara, N.
9. Alekseev, B.
10. Parnis, F.
11. Atduev, V.
12. Buchschacher, G.L.
13. Gafanov, R.
14. Corrales, L.
15. Borre, M.
16. Stroyakovskiy, D.
17. Alves, G.V.
18. Bournakis, E.
19. Puente, J.
20. Harle-Yge, M.-L.
21. Gallo, J.
22. Chen, G.
23. Hanover, J.
24. Wongchenko, M.J.
25. Garcia, J.
26. de Bono, J.S.
27. Mostrar todos los/as autores/as +